Trials / Withdrawn
WithdrawnNCT01405157
A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets Under Fasting Conditions
Phase 1, Open-label, Randomized, Single-dose, 2-treatment, Crossover Be Study Comparing Constituted Methylprednisolone Powder For Oral Suspension 4 Mg/ml To Methylprednisolone 16 Mg Tablet Under Fasting Conditions
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 21 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
A study to determine whether a new formulation of methylprednisolone suspension is bioequivalent to methylprednisolone tablets under fasting conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | methylprednisolone | constituted powder for oral suspension 4 mg/mL single dose at 16 mg |
| DRUG | methylprednisolone | tablets 16 mg single dose |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2012-02-20
- Completion
- 2012-02-20
- First posted
- 2011-07-29
- Last updated
- 2018-10-23
Source: ClinicalTrials.gov record NCT01405157. Inclusion in this directory is not an endorsement.